Suppr超能文献

新型口服青霉烯类药物SY5555在儿科领域的临床评价

[Clinical evaluation of a new oral penem, SY5555, in the pediatric field].

作者信息

Meguro H, Fujii R, Terashima I

机构信息

Department of Pediatrics, Teikyo University Ichihara Hospital.

出版信息

Jpn J Antibiot. 1995 Jan;48(1):41-8.

PMID:7699844
Abstract

A new oral penem antibiotic, SY5555, was evaluated for its safety and efficacy in 35 children with various bacterial infections. SY5555 was effective in 100% of scarlet fever, pharyngotonsillitis, pneumonia, otitis media, bacterial diarrhea, urinary tract infections and skin and soft tissue infections. The etiologic bacteria were eradicated except Salmonella sp. Side effects were observed in 3.5% cases; one was diarrhea and Candida dermatitis, one was loose stool, and one was Candida dermatitis. From these data, SY5555 is thought to be a safe and effective antibiotic in the pediatric field. Regular dose of suspension preparation is 15 mg/kg/day in 3 divided dosages, and when needed the dose may be doubled.

摘要

一种新型口服青霉烯类抗生素SY5555,在35例患有各种细菌感染的儿童中进行了安全性和有效性评估。SY5555对100%的猩红热、咽扁桃体炎、肺炎、中耳炎、细菌性腹泻、尿路感染以及皮肤和软组织感染有效。除沙门氏菌属外,病原菌均被根除。3.5%的病例出现了副作用;1例为腹泻和念珠菌性皮炎,1例为稀便,1例为念珠菌性皮炎。根据这些数据,SY5555被认为是儿科领域一种安全有效的抗生素。混悬剂常规剂量为每日15mg/kg,分3次服用,必要时剂量可加倍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验